Whitehawk Therapeutics
WHWK
39 hedge funds and large institutions have $54.6M invested in Whitehawk Therapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $56.4M → $54.6M (-$1.76M)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
22% less funds holding
Funds holding: 50 → 39 (-11)
66.31% less ownership
Funds ownership: 128.79% → 62.48% (-66%)
85% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$956K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$238K |
| 3 |
QF
QVT Financial
New York
|
+$174K |
| 4 |
Jane Street
New York
|
+$137K |
| 5 |
Squarepoint
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$3.36M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.72M |
| 3 |
SFA
Semmax Financial Advisors
Winston Salem,
North Carolina
|
-$145K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$120K |
| 5 |
Morgan Stanley
New York
|
-$108K |
WHWK Hedge Fund Activity: Q2 2025 in Review
39 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2025, worth a combined $54.6M — down 3.1% from $56.4M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of WHWK and 2 opened new positions — a net loss of 11 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $956K. The largest seller was BML Capital Management, exiting entirely with an estimated $3.36M sold.
- 39 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2025, down from 50 in Q1 2025.
- Funds reported $54.6M of Whitehawk Therapeutics stock for Q2 2025, down 3.1% quarter-over-quarter.
- 2 funds opened new Whitehawk Therapeutics positions in Q2 2025 and 13 closed out, a net change of -11 holders.
- The largest Whitehawk Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $956K added.
- The largest Whitehawk Therapeutics seller in Q2 2025 was BML Capital Management, an estimated $3.36M sold.
Based on aggregated 13F filings for Q2 2025.